GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/30831

Title:	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Authors:	Mora, J Castañeda, A Perez-Jaume, S Lopez-Pousa, A Maradiegue, E Valverde, C Martin-Broto, J Garcia Del Muro, X Cruz, O Cruz, J Martinez-Trufero, J Maurel, J Vaz, M A de Alava, E de Torres, C View more
Mesh:	Adolescent Adult Age Factors Antineoplastic Combined Chemotherapy Protocols Bone Neoplasms Child Child, Preschool Deoxycytidine Disease-Free Survival Docetaxel Humans Kaplan-Meier Estimate Odds Ratio Prognosis Prospective Studies Sarcoma, Ewing Spain Survival Rate Taxoids View more
Issue Date:	5-Sep-2017
Citation:	Br. J. Cancer.2017 Sep;(117)6:767-774
Abstract:	First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients.
PMID:	28787430
URI:	https://hdl.handle.net/20.500.12530/30831
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5589997.pdf		509.38 kB	Adobe PDF	View/Open